Wolfe Research Maintains Outperform on BioMarin (BMRN) March 16, 2026

Wolfe Research on March 16, 2026 maintained an Outperform rating on BioMarin Pharmaceutical Inc. (BMRN), keeping its BMRN analyst rating at Outperform and signaling a buy-on-weakness stance. The firm reiterated a $95 price target and said it would be a buyer on weakness. This note was published via StreetInsider and picked up by market feeds. The move keeps analyst sentiment steady and gives investors a clear reference point for valuation and risk.